alagebrium has been researched along with quinapril in 1 studies
| Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (quinapril) | Trials (quinapril) | Recent Studies (post-2010) (quinapril) |
|---|---|---|---|---|---|
| 83 | 10 | 31 | 652 | 220 | 47 |
| Protein | Taxonomy | alagebrium (IC50) | quinapril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.0083 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.11 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bierhaus, A; Cooper, ME; Gray, SP; Jandeleit-Dahm, KA; Jiaze, L; Pickering, R; Soro-Paavonen, A; Thomas, MC; Tikellis, C; Tsorotes, D; Watson, AM; Wong, B | 1 |
1 other study(ies) available for alagebrium and quinapril
| Article | Year |
|---|---|
Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.
Topics: Albuminuria; Animals; Apolipoproteins E; Diabetes Mellitus, Experimental; Fibrosis; Glomerular Mesangium; Glomerulonephritis; Glycation End Products, Advanced; Male; Mice; Mice, Knockout; Nephritis; Oxidative Stress; Quinapril; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Tetrahydroisoquinolines; Thiazoles | 2012 |